“Increasing Demand for More Targeted and Effective Therapies”
Key reason the anterior uveitis treatment market is trending is the increasing demand for more targeted and effective therapies. Traditional treatments, such as corticosteroids, are commonly used to manage inflammation but often come with significant side effects, especially when used long-term. This has driven the need for alternative therapies that offer greater precision in targeting inflammation without systemic effects.
Biologics, such as TNF inhibitors and interleukin inhibitors, have emerged as promising options, particularly for patients with chronic or refractory uveitis who do not respond well to steroids. In addition, innovations in drug delivery systems, such as suprachoroidal injections (e.g., XIPERE), allow for localized treatment with enhanced efficacy and reduced side effects, offering a significant advancement in managing uveitis. As a result, these developments are shaping the market, providing patients with more personalized and effective treatment options, which is driving the market’s growth.
